Table 1

Clinical and laboratory data in 41 diabetic children and adolescents with abnormal UAE, showing values in the whole group of patients and in those with MA or macroalbuminuria, treated or untreated

All patients (n = 41)Microalbuminuric patients (n = 32)Macroalbuminuric patients (n = 9)Untreated (n = 17)Treated (n = 24)
   Mean UAE values during the whole abnormal UAE period (mg/24 h)166.2 ± 127.9114.9 ± 59.4*356.9 ± 124.5157.7 ± 122.7187.3 ± 134.7
HbA1c during the whole abnormal UAE period (%)7.8 ± 1.37.7 ± 1.38.1 ± 1.37.6 ± 1.58.0 ± 1.3
Duration of abnormal UAE before the normalization (years)5.6 ± 4.6 (n = 33)4.7 ± 4.4 (n = 27)10.3 ± 2.5 (n = 6)2.1 ± 1.7* (n = 14)8.7 ± 4.2 (n = 19)
Duration of normalization after abnormal UAE (years)8.1 ± 5.9 (n = 33)8.3 ± 5.9 (n = 27)5.3 ± 4.5 (n = 6)9.6 ± 6.3 (n = 14)6.8 ± 5.8 (n = 19)
Duration of therapy before the normalization (years)4.6 ± 3.7 (n = 13)9.2 ± 2.6 (n = 6)6.0 ± 3.8 (n = 19)
Duration of therapy before stop therapy (years)2.4 ± 1.1* (n = 9)7.7 ± 2.3 (n = 2)3.4 ± 2.5 (n = 11)
Duration of remission off treatment (years)11.3 ± 5.3 (n = 9)9.0 ± 3.9 (n = 2)10.9 ± 5.0 (n = 11)
  • *P < 0.0001;

  • P < 0.01;

  • P < 0.025 vs. the respective group.